Floatz logo

eb103

HIV Associated Lymphoma

Estrella Biopharma, Inc.Cell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the HIV Associated Lymphoma cohort.

Asset / SponsorPhaseRating
Hst-Neets
Catherine Bollard
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 1CC
Ipilimumab
National Cancer Institute (NCI)
Phase 1CC
Ebv Mrna Vaccine
West China Hospital
Early Phase 1C

Same molecule, other indications

eb103 is also rated in:

B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
primary central nervous system lymphomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →